New approach in immunosuppressive strategies

Txcell strategy is to develop investigational products in a new class of autologous cellular immunotherapies that are uniquely designed to regulate the patient's own immune system.

Autologous cellular immunotherapies hold promise because they may provide patients meaningful clinical benefits with low toxicity.

TxCell develops innovative treatments for Crohn's (phase I/IIa) and Rheumatoid Arthritis patients (pre-clinical stage).

TxCell is a spin-off from the French Medical Research Institute (INSERM) .